3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
9
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Interventions
Cytarabine
23
Mitoxantrone
9
Etoposide
8
Idarubicin
5
Filgrastim
5
tipifarnib
4
fludarabine phosphate
4
Daunorubicin
4
Cyclophosphamide
4
Topotecan
3
Sorafenib
3
Clofarabine
3
Bortezomib
3
Azacitidine
3
tanespimycin
2
alvocidib
2
Peripheral Blood Stem Cell Transplantation
2
Imatinib Mesylate
2
Granulocyte Colony-Stimulating Factor
2
Everolimus
2
Cladribine
2
Carboplatin
2
Busulfan
2
Arsenic Trioxide
2
venetoclax
1
veliparib
1
trebananib
1
sargramostim
1
romiplostim
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Monocytic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn